Michel Azizi
Latest contributions
Patient selection for renal denervation in 2023
17 May 2023 – From EuroPCR 2023
While many clinical studies have demonstrated the superiority of renal denervation, the question that Felix Mahfoud asks Michel Azizi is when and in which patients to use this technique. Referring to the new consensus guidelines, our hypertension expert provides some answers in this exclusive interview recorded during EuroPCR 2023....
Comeback of renal denervation: The ESC Council on hypertension/EAPCI clinical consensus statement
16 May 2023 – From EuroPCR 2023
Ready to rejuvenate your memory of this session tackling on renal denervation? Investigate these slides and review the take home messages.
EuroPCR 2022 Hotlines / Late-Breaking Trials in hypertension management: SPYRAL-HTN ON MED, radiance HTN SOLO and TRIO, and more!
17 May 2022 – From EuroPCR 2022
Find out more about various studies & registries in hypertension management! Blood pressure and MACE reductions after renal denervation: 3-year GSR results, patient-level pooled analysis of ultrasound RDN in radiance-HTN SOLO and Trio, and SPYRAL-HTN ON MED 3 year data.
Crossover results from the RADIANCE-HTN SOLO trial
26 Jun 2020 – From PCR e-Course 2020
Watch this session if you want to learn about latest results from RADIANCE-HTN SOLO cohort and to review blood pressure results following crossover to ultrasound RDN in patients originally randomised to the sham arm in RADIANCE-HTN SOLO.
Videos included on this page: the Hot Line presentation, an...
The resurgence of renal denervation
25 Jun 2020 – From PCR e-Course
Following the latest trial results showing the safety and efficacy of renal denervation to treat hypertension, this session will provide you with a high-level update on where we stand currently and where we are moving in the near future.
This session was originally presented during PCR e-Course...
Ultrasound renal denervation: RADIANCE-HTN SOLO results
What is the latest evidence on the efficacy and safety of ultrasound renal denervation in treating hypertension? Reintroducing antihypertensive medication to patients previously treated with renal denervation is under discussion as Felix Mahfoud, Michel Azizi and Ajay Kirtane consider the 6-month results from the RADIANCE-HTN SOLO...
Renal denervation for hypertension treatment: What have we learnt recently?
With the results from 3 recent randomised trials and with 2 technologies, Michel Azizi (France) asks Felix Mahfoud (Germany) about the return of renal denervation not only as a treatment of resistant hypertension but also its use in non-end-stage disease and its application in other fields....
Catheter-based renal denervation – Back in routine clinical practice?
23 May 2019 – From EuroPCR 2019
Consult this session on catheter-based renal denervation to learn about recent studies, the "ideal patients", the pre-procedural planning and procedural aspects of renal denervation, and more!
RADIANCE-HTN SOLO: six-month results of renal denervation in patients on medications using the ReCor Paradise endovascular ultrasound system in a randomised, blinded, sham-controlled study
23 May 2019 – From EuroPCR 2019
Consult this session to learn all about the latest results from the RADIANCE-HTN SOLO cohort at the 6-month time point to assess efficacy of renal denervation in patients after medication titration.
What's new in hypertension treatment – An update for interventionists
23 May 2019 – From EuroPCR 2019
Consult this session to discover the updates in hypertension treatment: learn about new devices for hypertension management, how to apply the new hypertension guidelines in clinical practice, and more!
